Synapse - Howard Scher

Results (1133)

Targeting reciprocal feedback inhibition in the clinic: ARN509 and PI3K pathway inhibition in patients with metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Rathkopf, D. E.; Carver, B. S.; Chen, Y.; Morris, M. J.; Danila, D. C.; Slovin, S. F.; Autio, K. A.; DeNunzio, M.; Sawyers, C. L.; Scher, H. I.
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

A randomized, open label, multicenter, phase 3, 2-arm study of androgen deprivation with leuprolide (L), +/- docetaxel (D) for clinically asymptomatic prostate cancer (PC) subjects with a rising PSA following definitive local therapy: Safety results

Meeting Abstract

Morris, M. J.; Gleave, M. E.; Armstrong, A. J.; Carducci, M. A.; Saad, F.; Lacuna, K. P.; Scher, H. I.
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

Effect of concomitant medication use on outcomes of ties and placebo arms of the COU-AA-301 and COU-AA-302 studies of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Hamilton, R. J.; Li, J. H.; Naini, V.; San Kheoh, T.; De Porre, P.; Molina, A.; Lelbowitz-Amit, R.; de Bono, J. S.; Scher, H. I.; Ryan, C. J.; more...
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

Pathologic correlation of 18F-16 beta-fluoro-5 alpha-dihydrotestosterone (FDHT) and FDG PET in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Feldman, J. L.; Fox, J. J.; Martinez, D. F.; Autio, K. A.; Durack, J. C.; Humm, J.; Schoder, H.; Gavane, S. C.; Curtis, K. R.; Balakirsky, S. M.; more...
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

Molecular characterization of circulating tumor cells (CTC) and CTC subpopulations in baseline and progressive metastatic castration resistant prostate cancer (mCRPC)

Meeting Abstract

Dittamore, R.; Louw, J.; Krupa, R.; Danila, D. C.; Arslan, Z.; Schreiber, N. A.; Bales, N.; Marrinucci, D.; Scher, H. I.
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

Phase 3, randomized, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients (pts) with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) (ELM-PC 4 trial)

Meeting Abstract

De Wit, R.; Fizazi, K.; Jinga, V.; Efstathiou, E.; Fong, P. C. C.; Wirth, M.; Suzuki, K.; Moran, S.; Wang, L.; Akaza, H.; more...
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

A phase I study of DSTP3086S, an antibody-drug conjugate (ADC) targeting STEAP-1, in patients (pts) with metastatic castration-resistant prostate cancer (CRPC)

Meeting Abstract

Danila, D. C.; Szmulewitz, R. Z.; Baron, A. D.; Higano, C. S.; Scher, H. I.; Morris, M. J.; Gilbert, H.; Brunstein, F.; Lemahieu, V.; Kabbarah, O.; more...
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

The antitumor effects of PI3K beta inhibitors in PTEN negative prostate cancer are enhanced by inhibition of reactivated PI3K alpha signaling

Meeting Abstract

Schwartz, S.; Carver, B. S.; Wongvipat, J.; Rodrik-Outmezguine, V. ; Destanchina, E.; Trigwell, C.; Barry, S.; Baselga, J.; Chandarlapaty, S.; Scher, H. I.; more...
Cancer Research (2014)

Fulltext@MSK | Save

ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone acetate (AA)

Meeting Abstract

Rathkopf, D. E.; Antonarakis, E. S.; Shore, N. D.; Tutrone, R.; Alumkal, J. J.; Ryan, C. J.; Saleh, M. N.; Hauke, R. J.; Bandekar, R.; Maneval, E. C.; more...
Cancer Research (2014)

Fulltext@MSK | Save

Initial PET imaging and pharmacokinetic results from a Phase I/II study of Zr-89-labeled anti-STEAP1 antibody in metastatic castrate-resistant prostate cancer (mCRPC) patients

Meeting Abstract

Carrasquillo, J. A.; Danila, D. C.; Beylergil, V.; O'Donoghue, J. A.; Cheal, S. M.; Ruan, S. T.; Pandit-Taskar, N.; Fox, J. J.; Fleming, S. E.; Zanzonico, P. B.; more...
Cancer Research (2014)

Fulltext@MSK | Save